At Audien Hearing, our mission is simple: make hearing healthcare accessible to the people who need it most. That belief puts us inside one of the most complex supply chains in modern medicine, one where the safety and integrity of every product depends on infrastructure most people never see. To understand that infrastructure, we spoke with Scott Hietpas, CEO of Computype. Computype provides labels for 80% of the blood supply in North America, supporting the safe identification and traceability of critical blood products: that single fact tells you everything about the standard Scott holds his company to. What follows is a conversation about what it takes to earn that kind of trust, and why every company in healthcare should care about the answer.
Q: Computype provides labels for 80% of the blood supply in North America: that is a staggering number. How did one company come to be responsible for that much of something so critical?
A: We got here by solving a problem that others in the industry struggled with for years. Blood product labels need to perform in ways that standard labels cannot support.. They have to adhere to flexible bags that flex, compress, and expand through refrigeration, transport, and handling. They have to stay scannable through cold-chain conditions that destroy conventional adhesives. They have to perform across hundreds of touchpoints, from donation center to hospital, without a single failure. We’ve built adhesive formulations specifically for blood bag substrates, validated performance through protocols that simulate years of real-world conditions, and proved it with data rather than promises. Healthcare organizations that manage the blood supply make vendor decisions based on proof, not price. We provide that proof, and over decades, the market recognized it.
Q: Audien serves many older adults who are some of the highest consumers of transfusions and critical medical care. What does it mean for those patients that identification infrastructure like yours exists?
A: It means the healthcare system can keep its promises to them. When an older patient needs a transfusion during surgery, the blood administered has been positively identified at every stage from donation through delivery. The label serves as proof that the contents are accurately labeled, have been handed as required, and are safe to use. Without that proof, the unit cannot be administered. As the company behind 80% of North America's blood supply identification, we are part of a system that makes the most critical moments in patient care possible.
Q: How does labeling and traceability factor into building a brand consumers can actually trust?
A: Serialization is the foundation of consumer trust at scale. When every unit carries a unique identifier from the point of manufacture, that identifier becomes the thread connecting the product to its entire history: manufacturing lot, quality inspection, distribution pathway, and arriving to the end consumer. If a consumer questions what they received, serialization provides an immediate, verifiable answer. If a recall is necessary, it becomes targeted rather than sweeping, protecting consumers with unaffected units while reaching those who need action. For any company building long-term credibility, that infrastructure is the operational backbone of the promise you’re making to every customer who trusts your product with their health.
Q: What is the cost of getting identification wrong in healthcare, at the scale Computype operates?
A: The cost is significant - measured in both wasted product that was labeled incorrectly, and the patients who don't receive the healthcare they need. A blood bag with a failed label is destroyed. In a system where supply is always constrained against demand, every destroyed unit represents a patient whose surgery was delayed, a treatment that was harder to complete, a margin of safety that narrowed. Multiply one failed label across millions of blood products annually and the consequences become systemic. Engineering identification that never fails isn’t a quality standard: it’s a patient safety obligation.
Q: For a company at any scale, what separates an identification system worth trusting from one that only looks the part?
A: When performance is validated under actual conditions, not just ideal ones. Ask any supplier to prove their labels perform in your specific environment: the temperatures, humidity levels, substrate materials, and handling conditions your products actually face. Generic suppliers cannot provide that data because they’ve never tested for it. Second, it’s crucial to build serialization into your process from day one. Companies that retrofit traceability after the fact spend more, achieve less, and carry more regulatory risk than those who architect it in from the start. The companies that earn lasting trust are the ones that treat identification infrastructure as a foundational investment, not a line item to minimize. In a space where the people depending on your products are at their most vulnerable, that standard is the only one worth building to.
Learn more about Computype's identification and traceability solutions at Computype.com.
